[{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"||ACE2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"ACE2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Kwality Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"INDIA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"ACE2 receptor","graph1":"Hematology","graph2":"Preclinical","graph3":"Kwality Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kwality Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kwality Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rosalind Franklin University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"ACE2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Rosalind Franklin University","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rosalind Franklin University \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rosalind Franklin University \/ Inapplicable"},{"orgOrder":0,"company":"Scienture","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"ACE2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Scienture","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Scienture \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scienture \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Losartan

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Generic of Losartan potassium and hydrochlorothiazide tablets are been approved by FDA, indicated for hypertension to lower blood pressure and to reduce the risk of stroke.

                          Product Name : Cozaar-Generic

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          September 30, 2023

                          Lead Product(s) : Losartan Potassium,Hydrochlorothiazide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Granules India

                          02

                          Lead Product(s) : Losartan Potassium

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Losartan potassium prevention of angiotensin II binding causes vascular smooth muscle relaxation, lowering blood pressure. Angiotensin II would otherwise bind to the AT1 receptor and induce vasoconstriction, raising blood pressure.

                          Product Name : Cozaar-Generic

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          February 27, 2023

                          Lead Product(s) : Losartan Potassium

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Granules India

                          03

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Arbli (losartan potassium) is an angiotensin II receptor blocker indicated for hypertension, to lower blood pressure in adults and children greater than 6 years old.

                          Product Name : Arbli

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          March 18, 2025

                          Lead Product(s) : Losartan Potassium

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Kwality Pharmaceuticals gains RCGM approval for preclinical toxicity studies of recombinant Erythropoietin, advancing its biologics portfolio and targeting CKD-related anemia treatment.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          January 02, 2025

                          Lead Product(s) : Losartan Potassium

                          Therapeutic Area : Hematology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Rosalind Franklin University

                          Country arrow
                          AAN
                          Not Confirmed

                          Rosalind Franklin University

                          Country arrow
                          AAN
                          Not Confirmed

                          Details : Erythropoietin during cardiac arrest exerts protection by either preventing apoptosis of cardiac myocytes, smooth muscle cells, endothelial cells, or by increasing endothelial production of nitric oxide.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          February 02, 2023

                          Lead Product(s) : Losartan Potassium

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank